- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04322279
Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.
Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. (CoV-CONTACT-SERO)
In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on March, 16th 2020.
Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital.
Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action.
Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection.
In this study, we aim to evaluate the virological and clinical outcomes of subjects following a contact at high/moderate risk of SARS-CoV-2 acquisition, in community-subjects and/or healthcare workers.
The study population is represented by all subjects who had a contact with laboratory-confirmed SARS-CoV-2 cases and whose contact was considered to be at high/moderate risk of SARS-CoV-2 acquisition.
This include both children and adult subjects, subject without social security, and healthcare workers.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Procedures added by the research:
Blood sampling for determination of the presence of SARS-CoV-2 type M immunoglobulins or type G immunoglobulins.
Blood sampling for whole exome sequencing
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Besançon, Frankrike, 25030
- Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon
-
Bordeaux, Frankrike, 33076
- Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin
-
Clermont Ferrand, Frankrike, 63000
- Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand
-
Dijon, Frankrike, 21 079
- Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne
-
Grenoble, Frankrike, 38043
- Centre d'investigation clinique 1406 CHU Grenoble
-
Lille, Frankrike, 59037
- Centre d'Investigation Clinique 1403 -CHU Lille
-
Paris, Frankrike, 75010
- Centre d'Investigation Clinique Hôpital Saint Louis
-
Paris, Frankrike, 75018
- Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard
-
Paris, Frankrike, 75679
- Hôpital Cochin CIC 1417 Bâtiment Lavoisier
-
Rennes, Frankrike, 35033
- Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou
-
Saint Denis, Frankrike, 97400
- Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord
-
Saint Etienne, Frankrike, 42055
- Département maladie infectieux CHU Saint Etienne
-
Saint-Pierre, Frankrike, 97448
- Centre d'Investigation Clinique Ile de la Réunion CHU sud
-
Tours, Frankrike, 37000
- Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau
-
Vandœuvre-lès-Nancy, Frankrike, 54511
- Centre Investigation Clinique 1433 CHRU de NANCY
-
-
-
-
-
Cayenne, Fransk Guyana, 97306
- Service de Maladies infectieuses et tropicales Centre hospitalier
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- High/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case;
- Within the 14 days following the last contact with a laboratory-confirmed SARS-CoV-2 case;
- Obtaining informed consent.
Exclusion Criteria:
- Subject included in the CoV-CONTACT study
- Subject deprived of freedom
- Subject under a legal protective measure
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of subjects with SARS-CoV-2 positive serology at day 30 following the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.
Tidsramme: 30 days (+/-7)
|
Positive serology defined as the presence of SARS-CoV-2 IgM or IgG and assessed by ELISA, microneutralisation assay
|
30 days (+/-7)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Factors associated with a SARS-CoV-2 positive serology at day 30 (+/-7);
Tidsramme: 30 days (+/-7)
|
Positive serology defined as the presence of SARS-CoV-2 IgM or IgG and assessed by ELISA, microneutralisation assay
|
30 days (+/-7)
|
Time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.
Tidsramme: 365 days (+/-30)
|
ELISA, microneutralisation assay
|
365 days (+/-30)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Xavier Duval, MD, Institut National de la Santé Et de la Recherche Médicale, France
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- C20-16
- 2020-A00609-30 (Registeridentifikator: RCB-ID)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Koronavirus
-
National Institute of Allergy and Infectious Diseases...Naval Medical Research Center; SAb Biotherapeutics, Inc.FullførtMidtøsten respiratorisk syndrom CoronavirusForente stater
-
Bursa Yüksek İhtisas Education and Research HospitalUkjentCoronavirus som årsak til sykdommer klassifisert andre stederTyrkia
-
King Abdullah International Medical Research CenterFullførtMidtøsten respiratorisk syndrom Coronavirus (MERS-CoV)Saudi-Arabia
-
King Abdullah International Medical Research CenterUniversity of OxfordFullførtMidtøsten respiratorisk syndrom CoronavirusSaudi-Arabia
-
University Hospital, Basel, SwitzerlandsciCORE University of Basel; Leonhard Med IT ETH Zurich; Swiss Institute...RekrutteringSARS Coronavirus (SARS-CoV-2) infeksjonSveits
-
National Institute of Allergy and Infectious Diseases...Tilbaketrukket
-
National Institute of Allergy and Infectious Diseases...Tilbaketrukket
-
Inovio PharmaceuticalsCoalition for Epidemic Preparedness InnovationsFullførtMidtøsten respiratorisk syndrom Coronavirus (MERS-CoV)Libanon, Jordan, Kenya
-
Texas A&M UniversityM.D. Anderson Cancer Center; Baylor College of Medicine; Cedars-Sinai Medical... og andre samarbeidspartnereAktiv, ikke rekrutterendeKoronavirusinfeksjon | Koronavirus | Coronavirus som årsak til sykdommer klassifisert andre stederForente stater
-
National Institute of Allergy and Infectious Diseases...PPD; University of Washington; Vanderbilt University Medical Center; Implicit...AvsluttetAlvorlig akutt respiratorisk syndrom Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19)Forente stater